Evonik Industries AG (EVK) Earnings Call Transcript & Summary

November 3, 2026

Deutsche Boerse Xetra DE Materials Chemicals earnings

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and thank you for joining the Q3 2026 Earnings Conference Call. This is Shari, your Chorus Call operator. <<operator_script>> Please note that this conference is being recorded. <<operator_script>> Recording this conference for publication or broadcast is not permitted. Right now, I'm happy to turn things over to Dr. Claus Rettig, our Interim CEO. You may proceed.

Claus Rettig

executive
#2

Yes, good morning, and welcome to our quarter 3 earnings conference call, held for the first time from our new head office here in Essen. Thank you, everyone, for joining today. Since we have been in a new Executive Board setup since the end of August, let me begin with a few words about myself. Many of you, I hope, know me as a familiar face by now. But let me give you a little background. I am a chemist by education and joined Evonik more than 35 years ago. Over the years, I have worked in several leadership positions in Germany, South Africa, Japan and Singapore. For the last 4 years, I have been heading the Asia region and have been an associated member of the Evonik Executive Board. I also served as an interim CFO from December 2025 until the beginning of May '26. And my start as an interim CEO was, therefore, let's call it, very smooth from my point of view. So we have a very competent and well working management team. While Christian Kullmann is recovering from a surgery, there is absolutely no standstill here at Evonik. We continue to execute our strategy with full speed. Before we come to the strategy execution and our excellent financial performance in the quarter 3, a few words on the BASF takeover situation.

Claus Rettig

executive
#3

As you all know, based on what we've learned up to this point, we've chosen not to negotiate with BASF. That being said, we will have a purely informational and confidential exchange with BASF so we can explain where we stand and give them a chance to lay out their rationale along with the main considerations driving their interest. I'd ask for your understanding that we won't be commenting any further, including during today's Q&A session. Our full focus stays on our strategic direction and on developing as an independent company. I'll show that now by presenting the road map toward our most important midterm objective: a return on capital employed of around 11% by 2029. After that, Michael will discuss our continued strong operating performance in quarter 3. Then we'll wrap up the presentation with the outlook for this year. Over the next 3 years, we're going to reshape Evonik into a different company—one far more focused on its core, far more agile, and one that ultimately, by 2029 at the latest, will earn more than its cost of capital. That's something plenty of companies in our sectors are going to achieve.

Claus Rettig

executive
#4

I can only point you to a survey conducted recently that shows just 1 in 5 chemical industry companies is currently earning its cost of capital. And we have high confidence that we will get there. That confidence rests on tangible measures — plenty of them. We now examine return on capital in a more holistic way. At the top of the equation sits the increase in earnings in the form of adjusted EBIT — that isn't new; the existing strong emphasis on growth and efficiency will carry on. That same strict focus now applies to the denominator, targeting a reduction in capital employed. In a minute we'll show you the heightened attention to CapEx and net working capital for the years ahead. Nearly as important, the entire management team is, as we put it, laser focused this time on execution. Through launching portfolio change, through driving Evonik Tailor Made, and through investing in new solutions and sites, over the last years we have laid the groundwork for strong financial success. The time has now come to take the financial — final execution steps and to harvest the results. Our strong performance in 2026, with return on capital employed gaining more than 2 percentage points, tells us we are heading in the right direction.

Claus Rettig

executive
#5

I won't walk you through every slide we've prepared for today; instead, we'll just spotlight 1 example for each of the 5 return on capital employed levers. Growth matters most of all these levers. For a company to succeed over the long run, it has to grow. As you know, that's not easy in chemicals right now, but it is achievable, and we are seeing it happen. Growth at Evonik won't stem from 1 single new product or plant. It will result from a combination of factors: launching a completely new product and solutions, taking existing products into new markets, improving our planned utilization and raising product contribution margins, and therefore delivering an EBITDA margin expansion. Leading the way for our future sales growth are products developed within our 3 innovation growth areas. These products target markets that by far outgrow GDP. Take our biotech platform, for instance — it already posts a few hundred million euros of sales. That's an incredibly strong basis we have for driving further growth, as customers shift toward bio-based products in cosmetics, for farmers, but also in some industrial applications such as coatings. The second big pillar concerns efficiency. Since the end of 2023, we have been tailoring our organization to better fit our business needs and to become more agile, while at the same time keeping our cost base under control.

Claus Rettig

executive
#6

Offsetting inflation is the floor, and every extra saving feeds into the earnings growth we're targeting. Phase one of Evonik Tailor Made is nearly finished, and we launched phase two of that program in the middle of this year. That phase now works in a more holistic way, bringing every business optimization and administrative program together under a single roof. We have solid evidence of the progress we're making. Headcount is dropping quickly — more than 700 already in this year's low. We announced 3 site shutdowns during this year. That's a level of decisiveness we haven't shown before. On top of that, we're completing divestments. The Oxeno sale will be signed over the coming months. After that, Evonik will represent just 1/3 of the chemical activities at the chemical Pakman. For our infrastructure business called SYNEQT, which serves Mal, we'll find a new best owner shortly afterward. Naturally, we'll run these processes keeping all our stakeholders in mind, but above all our employees, and secure the best future for these 2 assets. We'll concentrate on what a specialty chemical company like ours ought to concentrate on, namely our business, our customers — custom solutions and advanced technology segments — to deliver benefits to our customers and to our end users.

Claus Rettig

executive
#7

Infrastructure services would be better off in the hands of infrastructure specialists or owners of large-scale integrated chemical parks. The proceeds from the divestment will be deployed into investments where we see our future — in additives, and in biotech for growth markets. Now Michael will take over as we shift from increasing earnings to reducing capital employed. Michael, the floor is yours.

Michael Rauch

executive
#8

Thank you, Claus. I'd also like to welcome everyone joining us. As Claus mentioned at the outset, capital employed has become a larger priority than it was previously. Beginning with CapEx, a consistent decline has been visible across recent years. That pattern is set to persist. Our run rate for CapEx looks to be even lower than it stands today — roughly EUR 700 million across the years ahead. This mirrors how our portfolio has been reshaped toward less capital-intensive operations that deliver higher returns, such as additives or biotech solutions. A CapEx level sitting below our historic depreciation and amortization therefore offers solid evidence that our strategy is being executed. It is plainly not an indication that we are underinvesting. Moreover, once Oxeno and SYNEQT have been exited, the CapEx requirements will drop even more. To bring capital employed down over the years to come, we will likewise cut our net working capital needs. In recent years, we had to undertake substantial year-end net working capital optimization measures, ultimately landing at a net working capital to sales ratio of around 80%. We are aiming for a net working capital to sales ratio of 17%, and that figure is far more balanced across the year. Toward that goal, we will, among other measures, harness the power of artificial intelligence to optimize inventory management further and to improve administrative processes for collecting and executing payments.

Michael Rauch

executive
#9

Now turning to how things went in this year's third quarter. Adjusted EBITDA for Q3 climbed 40%, reaching EUR 629 million. That figure aligns precisely with both Q2 and what we had guided for Q3 at the time. Higher prices in Advanced Technologies and in our C4 business were the main drivers behind the gain. Volumes in advanced technologies also increased. As we expected, methionine had a robust third quarter, with price increases now flowing through in full, and other businesses did well too, even as some Asian competition gradually returns. For instance, we saw strong volumes in polymers and solid pricing for cross-linkers once more. That demonstrates the strong performance isn't merely the result of supply chain disruptions slowly fading. Our results clearly show that customers value our solutions and services, along with our supply reliability. That won't disappear again. Cost savings contributed nicely, whereas higher bonus provisions worked against us. As always, that is mostly apparent in the other line, which is more negative than a year ago. One note on adjustments: as we projected on our Q2 results call, we have now booked a provision for phase two of the Evonik Tailor Made program in Q3.

Michael Rauch

executive
#10

The figure is slightly above EUR 300 million, and we anticipate a further high double-digit million euro sum in Q4 once every negotiation has been completed. And as we already showed in Q2, we are once again capable of turning that robust operating performance into cash. During Q3, our free cash flow improved substantially versus the prior year, by over 20%. And...

Operator

operator
#11

Everyone, kindly stay on the line. We’ve lost the connection to the speaker. The conference will resume in a moment. Thank you. You’re back on the line—please proceed. Everyone, kindly stay on the line. The conference will resume in a moment. You’re back on the line—please proceed.

Michael Rauch

executive
#12

Alright, I've just found out that the line dropped, unfortunately. So let's go ahead and pick things back up. I was talking about the over EUR 1.7 billion in adjusted EBITDA on the books following the first 9 months. So it probably won't come as a surprise that we're confident about delivering earnings in the upper half of our guidance range. That also implies earnings growth in Q4. On return on capital employed, we've now raised our guidance and expect more than 8%, and with that, we're making solid progress toward earning more than our cost of capital. Looking at Q4, we still need to work hard for a strong finish to 2026, since Q4 is typically a lower volume quarter because of seasonality across all businesses. Raw material and energy costs are rising while methionine prices are coming back to normal from the elevated Q3 levels. That said, this is a Q4-specific situation, which doesn't say much about next year. Order books look good as we head into 2027. We're seeing continued healthy demand. Our good business performance keeps going for longer, so we can already say today that we expect a good start into 2027. Now, back to 2026, we reiterate our cash flow guidance for 40% cash.

Michael Rauch

executive
#13

That ought to get us to robust cash generation of roughly EUR 850 million. That robust free cash flow is driving meaningful deleveraging. By the end of September, net financial debt had fallen by nearly EUR 400 million versus 1 year earlier. Leverage now sits at 2.1x and is continuing to trend lower. Our solid financial position was also reflected in Moody's upgrade to Baa1 at the end of August. And we'll keep strengthening our financial position further. With that, I'll hand back to Claus for some closing remarks.

Claus Rettig

executive
#14

Thanks, Michael. I hope we can still be heard well—there are some technical issues on the phone line. So let me recap what we just went through. As you can see, we're carrying out our strategy at full speed and with clear direction. We generate earnings growth via investments in growth and through efficiency improvements. And at the same time, we're shrinking our capital base. The divestments of Oxeno and SYNEQT are in progress. This will turn Evonik into a far more focused and agile company—more competitive and more profitable. We will report a ROCE of around 11% by 2029 at the latest, with continuously high cash generation. And with that, we can move to your questions. The floor is yours. Thank you.

Executive

executive
#15

One quick point from me. Before we open the Q&A, we'll reconnect to the main line once more. So, Cedric, over to you? Unfortunately, we're taking a brief pause, since as Claus mentioned, we're dealing with a few technical problems at the new headquarters. It's our first time in this room, so please give us 1 second. Thanks.

Operator

operator
#16

<<operator_script>> Our initial question comes from Chetan Udeshi at JPMorgan.

Chetan Udeshi

analyst
#17

Is my voice coming through?

Claus Rettig

executive
#18

Yes, Chetan, that's something we're able to do.

Chetan Udeshi

analyst
#19

I had a few questions. First, I was just listening to your remarks about Q4, where you mentioned that what you're seeing in Q4 is specific to Q4 and that you expect a good start in 2027. I'm a little confused about why it's different for Q4 and why it's better in H1 2027. I don't understand whether titanium prices are normalizing. Like, why would it be any better in 2027? Could you maybe explain that? And the second question I was going to ask — and I tried to ask this last time — it seems it's also somewhat visible in Q3, at least optically, which is your advanced technologies. You've beaten there, but then the custom solutions is weak, so I guess it's not hard to see this again as a quarter driven almost entirely by strong methionine prices. I know you referenced polymers being strong — maybe you can sort of help us understand what is going on in advanced technologies outside of just methionine trends, just so we can get confidence that this is not a one-off that doesn't continue into 2027?

Executive

executive
#20

Chetan, thank you for those 2 questions. Michael will take the first one, and then Claus will follow up on the question about advanced technologies versus custom solutions.

Martin Roediger

analyst
#21

Let me clarify what I actually said. First, on seasonality: the fourth quarter is typically weaker for us, and you've seen that pattern in earlier years too—that was my point about volume broadly. My second comment concerned methionine pricing, where levels that had been elevated in Q3 are easing somewhat. The third point was about Q4 relative to how 2027 begins. We do expect a good start to 2027, so while methionine prices are softening a little, the decline isn't severe—we're not falling off a cliff. We see solid business performance carrying on for longer. You yourself brought up polymers and cross-linkers, and we expect that effect to persist. That said, the fourth quarter typically brings inventory valuation and other year-end effects, which is essentially why we view Q4 as weaker than the strong start into 2027. For the second question, I'll pass it to Claus.

Claus Rettig

executive
#22

Yes. That question concerned how CEU performance compares with advanced technology. Well, first off, Chetan, let me be clear that methionine isn't the only factor here. And also on the — let's keep our focus on advanced technologies for now. Sure, methionine is strong, of course. We're already seeing normalization take place right now. So from that perspective, we had — peak prices came in June and July, but this year we're already on the path to normalization. And we can — we're quite confident that a solid business lies ahead of us as well. And we're seeing that already. I believe Michael brought it up, order books, Q1, which is why we describe it as a good start into Q1, but methionine isn't the whole story. We made that point. I think also in the papers we handed out, high-performance polymers, that is our business, extremely strong this year, winning back shares that we had lost previously. So we're well above market growth in polyamide worldwide, and that contributes to it. The cross-linker business is improved versus the prior year. So those are 3 elements of — on the advanced technology side. So customer solution, one could say, just a sales growth of 7% or EBITDA growth of 7%, is, of course, considerably lower than the other one, that's true.

Claus Rettig

executive
#23

In this case, we have numerous effects that we're tackling through changes to the portfolio. So there are areas that are clearly expanding, and there are ones that are contracting. And on the cosmetics side as well, the base ingredient business is genuinely contracting, and naturally that sits on top of growth elsewhere. And it plays a big part in what you're seeing in some of the lower one. Naturally, this business is also far less impacted by any sort of supply chain issues. So you could say it's pretty much untouched by all of that. So what you're seeing is pure business development. And through the portfolio measures and the investments, you've observed what we're doing on the healthcare business side too — an extremely strong emphasis on delivery systems, where we're extremely strong, redirecting our efforts toward the cosmetic solutions side, toward the specialty portion of the business. And naturally, I think, also cleaning up the portfolio of the underperforming part — or not performing the way we'd like it to perform — as of today. That too is progressing, and you'll see custom solutions taking on more and more of the role, which we observe in customer solutions as the growth engine throughout the portfolio.

Operator

operator
#24

Our following question comes from Martin Roediger at Kepler Cheuvreux.

Martin Roediger

analyst
#25

Three questions, really. First, what's the actual reason you're unwilling to discuss the BASF bid, even though it's a hugely important matter for investors? Second, separate from that BASF bid: we're aware the chemical sector, particularly in Europe, isn't truly in great shape — low growth, elevated costs, heavy bureaucracy, plus some geopolitical tensions. And you state that you wish to remain independent. But is there any situation in which you'd change your mind and say, okay, at this point we need to join forces with a big player? And the third question: Evonik wants to take an active part in the consolidation process within the chemical industry. Could you spell out your M&A criteria and your financial discipline?

Michael Rauch

executive
#26

Thanks, Martin. As you can probably guess, we aren't going to say anything about BASF, correct? So there isn't much point to that. But Claus will definitely share our own perspective on the portfolio and how we view potential M&A as well as consolidation within the sector.

Claus Rettig

executive
#27

Yes, as you mentioned. First off, I believe we've been fairly clear that we have a solid sense of what we're capable of achieving on our own going forward. And I think we've also consistently said that, yes, consolidation is an area in which we want to participate as an active player, and from that standpoint, we are — this is what we — I think this is our clear path. So I can only restate what I've said: we have clear priorities for capital allocation. So we are independent. We have good performance. We're in a very good market in our businesses, not everywhere. That's where we're cleaning up the portfolio. But that's where the focus for the future lies more than it did in the past. And therefore, we will also use these strengths to foster our growth. So the priorities for capital allocation on our part are also very clear and have not changed. Disciplined investment into our own growth. I think you also heard, Michael, when you look at the portfolio of the future, it's much less capital demanding. That's also an important element. Then, the second priority is and will be attractive shareholder returns through dividend, no doubt, has not changed, then strengthening the balance sheet, deleveraging in order to be ready if something that fits comes along.

Claus Rettig

executive
#28

The chemical sector is highly varied, so plenty of topics could be relevant to us should they come onto the market. We're carrying out our strategy, and I believe we've stated that we're doing so at full speed. You're aware that the divestments are already in place. All the major ones have already been announced. The optimization program has been announced and is moving forward, and deleveraging is also under way — that's progressing nicely. So, to repeat, if the right target appears, I can tell you we have a very clear picture of which targets interest us. Regarding consolidation, it has to be sensible. We invest in — we would only add things that strengthen our portfolio in growth fields, where we can deliver exceptional growth. Let me say it once more: growth matters so much for our industry, which is why any combination must center on growth. And — yes, so a complementary portfolio, primarily for Customer Solutions. I think everything we've said remains entirely unchanged. And that serves as the foundation for how we see the future, so to speak.

Operator

operator
#29

Our next question comes from Sebastian Bray at Berenberg.

Sebastian Bray

analyst
#30

I've got 2, please. First, regarding the interest cost we can expect across the coming 2 or 3 years — that's the adjusted net financing cost that has come up over recent years. Around the pandemic period, I believe it stood at roughly EUR 100 million. It may actually be somewhat above that. This year it could reach as much as EUR 160 million, EUR 165 million. Is there any debt refinancing or short-term rate sensitivity that would mean this figure might rise in '27 and '28, net of delevering effects? And any thoughts on the tax rate we should expect for that year? My second question concerns your — unfortunately unwell CEO, at least on a full-time basis, though I realize I'm asking something that straddles the line between private and public life. If you're unable to comment, that's fine. But do you have any indication of when Christian Kullmann might be well enough to come back to work?

Executive

executive
#31

Thanks, Sebastian. So Michael is going to begin with the interest costs and the tax rate, and after that, Claus can take over for the question.

Martin Roediger

analyst
#32

Yes. Thank you, Sebastian, for those questions. Well, as all of you are aware, interest rates — unfortunately, the markets remain high. So that has an effect on us as well, and that is why our interest costs are higher than they were in previous years. You know the debt instruments we have out there in the market. But you're also Claus, and I can only repeat what you said earlier: we are on a good path toward further deleveraging. We have our Oxeno divestiture. And the next 1 up is our SYNEQT divestiture, and we will also use those proceeds to pay that back, and then, all else being equal, our interest cost also go down. Your question was also about the tax rate, and I can be very precise here. So we have for 2027 a tax rate implied of about 25% here, so we will return to the usual level of tax rate, which we have as a run rate also originally projected for 2027 — sorry, for 2026 before we went into some special effects. With that, I hand over to Claus for the second question.

Claus Rettig

executive
#33

Yeah. Thanks, Sebastian. Thanks for asking about our CEO — I think that's really nice. I can't really tell you a whole lot; every so often I exchange messages with him on WhatsApp. He's at a rehabilitation clinic, where they put a lot of emphasis on patients focusing on their rehabilitation. So from that angle, we've also asked not to have too much back-and-forth. So unless — we don't have a clear picture of when he'll return. We still believe it will be the beginning of 2027. Nothing has changed on that...

Sebastian Bray

analyst
#34

That's useful. Best wishes to Christian and to you.

Operator

operator
#35

Stay on the line, please — the conference will resume in a moment. Our connection to the speakers dropped. Our next question comes from David Symonds at BNP Paribas.

David Symonds

analyst
#36

To start, the first 1 is yet another bridge 1 into 2027. Could you discuss what you expect for energy costs going into next year, along with your hedging position? Second, I'd like to ask about the EU Critical Chemicals Act — what your latest thinking is, what the next steps are, and which products you're hoping will make the list. Then finally, one more question on 2027. It's interesting to hear the confidence you have in the 2027 outlook based on the current order book, because I recall that earlier this year, you and peers found it difficult to extrapolate anything from the order book given how patchy it was. Could you explain what has changed, which end markets have become more reliable for you, enabling that confidence to be extrapolated into next year, and how customers are generally behaving as you see it today?

Executive

executive
#37

David, so the first item, energy costs, Michael is going to take. The second one, the critical chemical line, goes to Claus, and then the last one on end markets, back to Michael.

Michael Rauch

executive
#38

Yes. Thank you. I'll begin with the first one. And as you're aware, some uncertainty persists about how long the conflict will last and — actually, I should say the conflicts here in the world. And that does affect energy costs. So, with the caveat that we expect energy costs at roughly a similar level, there could be a small spike in prices. But then again, our energy exposure is well hedged too. So we have a hedge quota going into next year covering more than 50% of the energy that gets hedged on our side. So we do expect a level similar to 2026, with a slight spike up here, which we're prepared to take. With that, I'd hand over to Claus for a second question.

Claus Rettig

executive
#39

Thank you, Michael. I hope my voice is coming through clearly now, since we've had to rely on a mobile phone, which isn't our normal setup. So yes — critical chemical lines — let me give you some context here. The results of this critical chemical alliance were presented to the EU general assembly in October. And the chemical sector has once again been confirmed as a strategic industry for Europe, with emphasis placed on protecting existing production while speeding up the shift toward sustainable technologies. A preliminary list of critical molecules has also been put forward as the foundation for future industrial trade and funding measures. That list should be trimmed substantially by the end of this year so implementation can move faster. All told, 49 products appear on the list, and 8 of those come from us. I believe these are — yes, so it's — for instance, I can mention that methionine is among them, and also is among them too. They're genuinely critical for the value chain inside Europe and for food safety as well, as you know, so — but there are a few others on it too, though for us these are likely the most important ones, and we're quite confident they'll remain on it.

Claus Rettig

executive
#40

Then, one more question regarding the...

Executive

executive
#41

Regarding the end market, here's my perspective...

Claus Rettig

executive
#42

That wraps up how we see the end markets.

Executive

executive
#43

Michael, we’ll return to you.

Michael Rauch

executive
#44

I'll take that one. You asked about the order books for 2027 and how we see things developing as we head into 2027, so let's be clear here. This isn't the guidance call for 2027, but let me make a couple of remarks. First, we're not resting on this year's success, right? We're doing what's in our hands to be better placed in any environment. And we have growth investments, cost savings and portfolio optimization to come. So we want it will be definitely a much better company in 2027 though we do not know what the environment will really be like. What we've seen is that actually, our order books are picking up, and we have more visibility than we had basically during the difficult periods coming into the year 2026 and then moving into Q2. So the strong business performance that we currently see is continuing for longer. And therefore, we have a good start into 2027, comfortably above the level of this year's Q1. So to give you also some tangible examples from our businesses, well, you noticed yourself, the earnings base for Customer Solutions as a whole is not particularly high.

Michael Rauch

executive
#45

In Animal Nutrition, our entry position is stronger than it was 12 months ago. So the starting point for the expected price normalization sits higher than it did at the close of last year. Our backward integration is expected to deliver double-digit million euro cost savings across the year. In hydrogen peroxide, we are well positioned to benefit from growing semiconductor demand. Alongside that, our innovative nano-bubble technology is picking up momentum in meat disinfection applications, especially in the U.S., and that opens attractive new growth opportunities. And last 1 here in silica, just to mention, we are also benefiting from the capacity expansion in Charleston and expect further growth from customer-specific projects as well as new specialty applications. So all in all, we are more confident as we move into 2027.

Operator

operator
#46

Our next question comes from Jaideep Pandya at On Field Research.

Jaideep Pandya

analyst
#47

Let me start with the first one, which touches a bit on methionine. Could we walk through the puts and takes you're seeing in that market over the coming 4 quarters — specifically capacity additions versus demand? I'm also quite curious about the powder versus liquid dynamic there. The second question really concerns your portfolio beyond methionine: when you look at the core Evotec portfolio outside methionine, what does the competitive landscape look like today? Take something like crosslinkers, where you historically held very strong market share and then competition increased. So as you analyze your portfolio, are you confident it won't face the same level of competition coming out of China, which would put pressure on your returns? And the last question: obviously there are rumors about what you're seeking in terms of M&A. Should we think of Cosmetic Ingredients and health care as the main areas where you're looking to bolster your strength?

Executive

executive
#48

Jaideep, thanks a lot for those questions. Claus will begin with methionine, after that we'll turn to Michael regarding competitive dynamics across the 2 segments, and then it's back to Claus for the M&A focus areas.

Claus Rettig

executive
#49

Yes. So, on methionine — sorry, let me get to that. Yes, methionine, of course, is always a big topic of debate. So right now we have very strong operational performance, and that will carry on into Q4. As I mentioned before, prices peaked in June and July. Since then, we've been seeing a normalization trend, and volumes remain strong. And there's also the fact that earlier this year our customers saw that we could deliver — that we're a highly reliable supplier — and supply reliability is becoming a new competitiveness factor. That's certain. So, having said that, at present we have strong demand. We already have quite a bit booked for Q4. So we have a very good view on Q4. And we also have a very good view into Q1. This is, of course, with price normalization but a very strong volume trend at or above that level. So this year, we're going to grow slightly above market, and the market is still a very solidly growing market. When it comes to — you're asking about what's happening on the capacity side. So I think you know that CJ announced it will permanently close down its Malaysia plant.

Claus Rettig

executive
#50

So that got underway around roughly October. They still have, shall we say, stock left that they've been selling during this year. In our view -- so the capacity -- the capacity that's been announced for this plant is -- I believe it's somewhere near about 170 kt, 180 kt even, and -- but our belief is that they've only turned out 100 kt. So 100 kT is leaving the market. Sumitomo at present is down, and they've announced they'll remain down through the end of the year. So they've got some issues. And then beyond that, the new entrant, leading crop science, is the sole new competitor at this stage. In Inner Mongolia, they're adding -- they will bring in a further 100 Kt of the L-methionine. Right now, we aren't seeing anything going on there. It's already fairly cold in Mongolia. So there isn't much that can be done before the winter is over. So our expectation is that they'll come on stream perhaps in Q2 of next year using the new technology, so we'll have to watch how that performs. Even so, from a logistics standpoint, they're in a completely different territory. Then there are the extensions of the other extensions that have been announced, in particular Adisseo at the end of this year with 140 kT, all of which is known.

Claus Rettig

executive
#51

And this is a player already in the market with l-methionine. Players who are already there tend to act differently from new entrants. So we believe we're on fairly solid ground when we make assumptions about how the market will develop. And on that basis, this fits with what we've said about seeing a very solid start into 2027. And — yes, so perhaps I'll stop there on the methionine remarks.

Michael Rauch

executive
#52

Yes. So I'll handle the broader remarks about competition, which you raised — and of course, we always treat competition as something we take very seriously. But as Claus mentioned, we've also demonstrated all through 2026 that we were highly dependable. We served customers in the region, for the regions — every one of our customers. And that dependability has in fact produced market share gains, which we'll keep building on as we move into 2027. So our competitive position has improved. Now, you also brought up the growing competition coming from China. Just as a reminder, on the custom solutions side, we aren't especially exposed to that competitive pressure. And on the advanced technology side, we've actually taken substantial steps, as we noted earlier on this call and have also discussed over the last couple of conference calls, to significantly strengthen our cost position in advanced technology. And that is why the competitive landscape doesn't worry us, and we very much look forward to serving our customers with dependable service and the best solutions, just as we have done previously. And regarding your final point on M&A, of course, we don't comment on rumors, but for the general search fields <<inaudible>> over to Claus.

Claus Rettig

executive
#53

Yes. Thanks again, Michael. Yes. So M&A — as I mentioned, we don't comment on rumors at all, period. So — and when you look at it, I think there's also no view there. First of all, let me say that M&A is 1 element of growth, but we also — I think I said earlier — organic growth ranks #1 on our list of things to do. I can tell you that we're examining quite a few organic growth options, which we're exploring right now, at varying degrees of, let's say, stage. And, yes, so I can tell you we're looking into quite 4 projects in Asia. We'll be opening a new plant here in Essen next week. So that shouldn't be forgotten. That's something we're focusing on as number one. When it comes to M&A, as I said before, it has to fit, and it has to fit at a portfolio level. So where does it make sense? No — I think no surprise. We said custom solutions is the area we're focusing on. There's no doubt about it. Okay, Customer Solutions also spans different areas. We have a new business line in play that we're looking into, where I'd add on.

Claus Rettig

executive
#54

Broadly speaking on additives, we're strong in additives for growth fields. It's a key area for us. We're exploring Cosmetic Ingredients, Specialty Ingredients as a growth field, no question, and biotech. Those are the 3 areas where you'll see us concentrating when it comes to M&A where it makes sense. So maybe that gives you a bit more flavor of what we're looking for, what it could be, only to say. We have a solid list of interesting targets, but they also have to become available. And right now, we're focused on our own growth. But again, if something comes along that fits very well along these lines, then of course, we look into it.

Jaideep Pandya

analyst
#55

Let me just ask 1 follow-up, if I can, on that first point. What kind of capacity utilization do you have as of this year? I'm asking because I just want to get a sense of it — you haven't put money into this business for additional capacity across the last couple of years, or a few years, rather. So I'm just curious about when a need would arise, since the dynamic has shifted a great deal. And as you correctly noted, a few competitors have now exited the market. So what level of capacity utilization are you running at as of 2026?

Executive

executive
#56

Right. We won’t get into the precise utilization figure. As you know, the market is expanding at 3% to 4%, so additional capacity is needed. Claus noted that some capacity is also being retired. All in all, I believe we’re fine with the current state of the market. With that, I think we’ll wrap up the Q&A and return to Claus for closing remarks.

Claus Rettig

executive
#57

All right. Yes, indeed. Well, thank you all so much for those questions. And I apologize for the technical difficulties. Yes, this is coming from our new landlines here at the head office. We'll get this sorted out for the next quarters, guaranteed. And yes, thank you, everyone. That brings today's call to a close. We look forward to our conversations on the road over the coming days and weeks, when we'll have far more time. And we'll be making a particular effort to meet lots of players in the market, one-on-one, where we have much more time for discussion than we do right now. Thanks for now, and goodbye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Evonik Industries AG transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Evonik Industries AG earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Evonik Industries AG or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.